Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles P Sparrow

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Inflammatory Bowel Diseases|March 11, 2021
A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to ConceiveEmma Flanagan, Emily K Wright, Miles P Sparrow, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Journal of Crohn'S & Colitis|September 16, 2022
An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative ColitisSally Mortlock, Anton Lord, Grant Montgomery, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2025
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trialsChristopher Ma, Reena Khanna, Bryan R Maguire, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Gastroenterology|March 27, 2025
Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease ActivityRalley E Prentice, Emma K Flanagan, Emily K Wright, et al.
The American Journal of Gastroenterology|September 29, 2025
Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel DiseaseRobert D Little, Thisun C Jayawardana, Fan Zhang, et al.
Gastroenterology|April 12, 2016
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on InfectionMette Julsgaard, Lisbet A Christensen, Peter R Gibson, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Inflammatory Bowel Diseases|March 11, 2021
A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to ConceiveEmma Flanagan, Emily K Wright, Miles P Sparrow, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Journal of Crohn'S & Colitis|September 16, 2022
An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative ColitisSally Mortlock, Anton Lord, Grant Montgomery, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2025
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trialsChristopher Ma, Reena Khanna, Bryan R Maguire, et al.
Alimentary Pharmacology & Therapeutics|September 27, 2020
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposureEmma Flanagan, Peter R Gibson, Emily K Wright, et al.
Gastroenterology|March 27, 2025
Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease ActivityRalley E Prentice, Emma K Flanagan, Emily K Wright, et al.
The American Journal of Gastroenterology|September 29, 2025
Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel DiseaseRobert D Little, Thisun C Jayawardana, Fan Zhang, et al.
Gastroenterology|April 12, 2016
Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on InfectionMette Julsgaard, Lisbet A Christensen, Peter R Gibson, et al.
BMJ Open|July 20, 2024
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialRobert D Little, Jo McKenzie, Ashish Srinivasan, et al.
Pageof 10